Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

PURPOSE: Patients with transplantation-ineligible relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) fare poorly, with limited treatment options. The antibody-drug conjugate polatuzumab vedotin targets CD79b, a B-cell receptor component. METHODS: Safety and efficacy of polatuzumab vedot...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Sehn, Laurie H., Herrera, Alex F., Flowers, Christopher R., Kamdar, Manali K., McMillan, Andrew, Hertzberg, Mark, Assouline, Sarit, Kim, Tae Min, Kim, Won Seog, Ozcan, Muhit, Hirata, Jamie, Penuel, Elicia, Paulson, Joseph N., Cheng, Ji, Ku, Grace, Matasar, Matthew J.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2020
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7032881/
https://ncbi.nlm.nih.gov/pubmed/31693429
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.00172
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados